These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 30546748)

  • 1. Dramatic response to low-dose rivaroxaban in an Asian patient with deep vein thrombosis and pulmonary embolism.
    Yamaguchi J; Makino K; Kusunose Y; Higa S; Takagi T; Suzuki K; Lee T
    J Cardiol Cases; 2013 Aug; 8(2):e77-e80. PubMed ID: 30546748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and rationale for the Japanese Registry of Rivaroxaban Effectiveness & Safety for the Prevention of Recurrence in Patients with Deep Vein Thrombosis and Pulmonary Embolism (J'xactly) study.
    Okumura Y; Fukuda I; Nakamura M; Yamada N; Takayama M; Maeda H; Yamashita T; Ikeda T; Mo M; Yamazaki T; Hirayama A;
    BMJ Open; 2018 Jun; 8(6):e020286. PubMed ID: 29934383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.
    Ageno W; Mantovani LG; Haas S; Kreutz R; Monje D; Schneider J; van Eickels M; Gebel M; Zell E; Turpie AG
    Lancet Haematol; 2016 Jan; 3(1):e12-21. PubMed ID: 26765643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shorter Hospital Stays and Lower Costs for Rivaroxaban Compared With Warfarin for Venous Thrombosis Admissions.
    Margolis JM; Deitelzweig S; Kline J; Tran O; Smith DM; Bookhart B; Crivera C; Schein J
    J Am Heart Assoc; 2016 Oct; 5(10):. PubMed ID: 27792638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hospitalizations and Other Health Care Resource Utilization Among Patients with Deep Vein Thrombosis Treated with Rivaroxaban Versus Low-molecular-weight Heparin and Warfarin in the Outpatient Setting.
    Deitelzweig S; Laliberté F; Crivera C; Germain G; Bookhart BK; Olson WH; Schein J; Lefebvre P
    Clin Ther; 2016 Aug; 38(8):1803-1816.e3. PubMed ID: 27491278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful use of rivaroxaban in postoperative deep vein thrombosis of the lower limb following instability with warfarin: a case report.
    Schiavoni M; Coluccia A
    J Med Case Rep; 2016 Oct; 10(1):276. PubMed ID: 27716428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Cost Effectiveness Analysis of Rivaroxaban Compared to Warfarin for Deep Vein Thrombosis (DVT) Treatment in Ethiopia.
    Derseh MT; Solomon K; Tamene W; Beneberu W; Yayehrad AT; Ambaye AS
    Clinicoecon Outcomes Res; 2021; 13():821-834. PubMed ID: 34557006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rivaroxaban as an effective alternative to warfarin in a patient with atrial fibrillation, thrombophilia, and left atrial appendage thrombus: a case report.
    Scarano M; Casale M; Mantini C; Imbalzano E; Consorti C; Clemente D; Dattilo G
    J Med Case Rep; 2017 Apr; 11(1):97. PubMed ID: 28390428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism - the J-EINSTEIN DVT and PE program.
    Yamada N; Hirayama A; Maeda H; Sakagami S; Shikata H; Prins MH; Lensing AW; Kato M; Onuma J; Miyamoto Y; Iekushi K; Kajikawa M
    Thromb J; 2015; 13():2. PubMed ID: 25717286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rates of hospitalization among patients with deep vein thrombosis before and after the introduction of rivaroxaban.
    Merli GJ; Hollander JE; Lefebvre P; Laliberté F; Raut MK; Olson WH; Pollack CV
    Hosp Pract (1995); 2015; 43(2):85-93. PubMed ID: 25791984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial.
    Beyer-Westendorf J; Schellong SM; Gerlach H; Rabe E; Weitz JI; Jersemann K; Sahin K; Bauersachs R;
    Lancet Haematol; 2017 Mar; 4(3):e105-e113. PubMed ID: 28219692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight.
    Perales IJ; San Agustin K; DeAngelo J; Campbell AM
    Ann Pharmacother; 2020 Apr; 54(4):344-350. PubMed ID: 31672028
    [No Abstract]   [Full Text] [Related]  

  • 13. Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin.
    Fitzgerald RH; Spiro TE; Trowbridge AA; Gardiner GA; Whitsett TL; O'Connell MB; Ohar JA; Young TR;
    J Bone Joint Surg Am; 2001 Jun; 83(6):900-6. PubMed ID: 11407799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial.
    Campbell IA; Bentley DP; Prescott RJ; Routledge PA; Shetty HG; Williamson IJ
    BMJ; 2007 Mar; 334(7595):674. PubMed ID: 17289685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute pancreatitis complicated with deep vein thrombosis and pulmonary embolism: a case report.
    Herath HM; Kulatunga A
    J Med Case Rep; 2016 Jun; 10(1):182. PubMed ID: 27339635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rivaroxaban: practical considerations for ensuring safety and efficacy.
    Smythe MA; Fanikos J; Gulseth MP; Wittkowsky AK; Spinler SA; Dager WE; Nutescu EA
    Pharmacotherapy; 2013 Nov; 33(11):1223-45. PubMed ID: 23712587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective study of Rivaroxaban for central venous catheter associated upper extremity deep vein thrombosis in cancer patients (Catheter 2).
    Davies GA; Lazo-Langner A; Gandara E; Rodger M; Tagalakis V; Louzada M; Corpuz R; Kovacs MJ
    Thromb Res; 2018 Feb; 162():88-92. PubMed ID: 28416213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.
    Agnelli G; Gallus A; Goldhaber SZ; Haas S; Huisman MV; Hull RD; Kakkar AK; Misselwitz F; Schellong S;
    Circulation; 2007 Jul; 116(2):180-7. PubMed ID: 17576867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changing Patterns of Anticoagulation After Total Hip Arthroplasty in the United States: Frequency of Deep Vein Thrombosis, Pulmonary Embolism, and Complications With Rivaroxaban and Warfarin.
    Glassberg MB; Lachiewicz PF
    J Arthroplasty; 2019 Aug; 34(8):1793-1801. PubMed ID: 31005440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin: a comparison of patient self-injection with homecare injection.
    Wells PS; Kovacs MJ; Bormanis J; Forgie MA; Goudie D; Morrow B; Kovacs J
    Arch Intern Med; 1998 Sep; 158(16):1809-12. PubMed ID: 9738611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.